Regulatory approvals for Crispr Therapeutics' CASGEVY program are increasing, expanding the potential market for the treatment. Government support, including public funds, is likely to be available ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

SAN DIEGO--(BUSINESS WIRE)--CRISPR QC, a biotechnology start-up based in San Diego, is pleased to announce a major stride in its ongoing Series A funding round. Known for their CRISPR Analytics ...

The invention has made it onto TIME’s 2025 Best Inventions list, in the food and drink category, and would be the first new ...

Nex-z is one of two late-stage projects on the go at Intellia, a specialist in CRISPR gene-editing co-founded by Nobel Prize ...

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...

Cigna Group will eliminate prescription drug rebates in many of its commercial health plans in 2027, a practice that has ...

CRISPR-Cas9 genome editing enzyme. [Artur Plawgo / iStock / Getty Images Plus] We need a patient-first approach for any variant in any patient, whomever, wherever they are. Each and every patient ...

* Maxcyte will supply systems Co and Casebia as part of license agreement and will receive upfront, milestone, and sales-based payments * Says commercial license builds on an existing research and ...